Veracyte’s Nasal Swab Test Gets Clinical Validation for Lung Cancer Risk Assessment
Clinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read MorePosted by Andy Lundin | Dec 1, 2023 | Lung Cancer, Swabs |
Clinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read MorePosted by Chris Wolski | Nov 16, 2023 | Diagnostic Technologies |
Consolidation, legislation, new testing types, and a shift to more consumer-driven testing are some clinical laboratory predictions for 2024.
Read MorePosted by Andy Lundin | Nov 7, 2023 | Company News, Molecular Diagnostics |
Veracyte and Illumina will develop high-performing molecular tests as decentralized IVD tests on Illumina’s NextSeq 550Dx NGS instrument.
Read MorePosted by Andy Lundin | Nov 2, 2023 | Cancer |
The TruSightf Oncology 500 ctDNA v2 enables comprehensive genomic profiling of ctDNA from blood when tissue testing is not available.
Read MorePosted by Andy Lundin | Nov 1, 2023 | Cancer |
Researchers developed a highly sensitive blood test that detects a key protein produced by cancer cells, showing promise for early detection.
Read More